Ezyglip 20mg Tablet contains Teneligliptin 20mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor used primarily for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, Teneligliptin increases the levels of incretin hormones, which enhance insulin secretion from pancreatic beta cells and suppress glucagon release from alpha cells in a glucose-dependent manner. This dual action helps to regulate blood glucose levels effectively without causing significant hypoglycemia. Ezyglip is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. The 20mg dosage is convenient for once-daily administration, promoting patient compliance. Teneligliptin has a favorable safety profile, with minimal risk of weight gain and low incidence of adverse effects. However, it is important to monitor renal function and adjust therapy accordingly, as well as to be aware of potential allergic reactions or pancreatitis. Ezyglip should be used under medical supervision, with regular monitoring of blood glucose and HbA1c levels to ensure optimal therapeutic outcomes in diabetes management.